Xiaopeng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaopeng Sun has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Justin M. Balko
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
125 shared publications - Paula I. Gonzalez-Ericsson
Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA
121 shared publications - Violeta Sanchez
Department of Medicine, Vanderbilt University, Nashville, USA
121 shared publications - Melinda E. Sanders
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
118 shared publications - Susan R. Opalenik
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
114 shared publications - Ann Hanna
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
112 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 2 Representative images showing expected architectural expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 2 Representative images showing expected architectural expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 1 Scatter plots showing example of flow cytometry gating strategy:
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 1 Scatter plots showing example of flow cytometry gating strategy:
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Table S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Table S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 4 HLA-AB loss with unknown HLA-C expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 4 HLA-AB loss with unknown HLA-C expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplemental Figure 3 Heatmaps showing cell DAB intensity for each allele and antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplemental Figure 3 Heatmaps showing cell DAB intensity for each allele and antibody.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 5 Stromal TILs according to HLA-A, B and C loss or retained (conserved or regional loss) status for patient cohort with TNBC (A), HR + HER2- (B) and HER2+ breast cancer (C).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
Supplementary Figure 5 Stromal TILs according to HLA-A, B and C loss or retained (conserved or regional loss) status for patient cohort with TNBC (A), HR + HER2- (B) and HER2+ breast cancer (C).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from In Situ Detection of Individual Classic MHC-I Gene Products in Cancer